SA55 Injection: a Potential Therapy for the Prevention and Treatment of COVID-19

Summary

In this first-in-humans dose escalation study, SA55 will be evaluated for safety, tolerability, and pharmacokinetics. The study is intended to enable future studies of SA55-injection's efficacy in preventing and treating COVID-19.

Timeline

Start

2023-06-15

Primary completion

2023-10-30

Completion

2023-12-30

Publications

• Zhou Y, Meng X, Li J, Zeng G, Wang J, Cao Y, Hu C, Jin R. Safety, tolerability, and pharmacokinetics of anti-SARS-CoV-2 monoclonal antibody SA55 injection in healthy participants. Antimicrob Agents Chemother. 2025 Aug 6;69(8):e0056825. doi: 10.1128/aac.00568-25. Epub 2025 Jul 17.

Drugs

Indications